Ascites: Improvement in Reimbursement Policies is Likely to Boost The Market Growth at a CAGR of 4.0% During The Forecast Period 2017-2023 :

Pune, India, January 2018 /MRFR Press Release/- Market Research Future has a cooked research report on the ascites market.

Market Highlights

Ascites is the accumulation of fluid in the spaces between the abdomen and abdominal organs. It is the most common complication associated with cirrhosis, and its development is also a sign of significant portal hypertension. Other conditions that can cause ascites include hepatitis B, hepatitis C, congestive heart failure, kidney disease, and malignancy

Increasing prevalence of cirrhosis, favorable reimbursement scenario, rising occurrence of cancer, development of new drugs, and technological improvements are the key factors driving the ascites market.

However, complications associated with ascites treatment may hinder the growth of the market to an extent. Various complications have been observed with ascites treatment approaches such as bleeding, small bowel perforation, stent placement complications, post-procedural complexities, and others. Some of these complications are rare and life-threatening

The global ascites market is expected to grow at a CAGR of 4.0% during the forecast period 2017-2023.

Taste the market data and market information presented through more than 296 market data tables and figures spread over 251 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “ascites market research report–Global forecast till 2023.” 

Key Players in the Ascites Market

Some of key the players in the ascites market are Sequana Medical, BioVie, PharmaCyte Biotech Inc., Fresenius SE & Co. KGaA, BD, GI Supply, Medtronic plc, and others.

Regional Analysis

The Americas dominate the ascites market owing to the well-developed technology, high healthcare expenditure, rising prevalence of cirrhosis, and the presence of the leading players. According to the data suggested by the Centres for Disease Control and Prevention in 2015, around 1.6 % adults have been diagnosed with the chronic liver disease in the U.S. i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to the chronic liver disease and cirrhosis increased by 31% in the United States among individuals aged 45–64 years.

Europe holds the second position in the ascites market. It is expected that the support provided by the government bodies for research & development and the increase in a number of surgeries drives the market in European region. The liver is also very prevalent in European region. Owing to the increasing alcohol consumption and obesity, liver cirrhosis is the third most common cause of premature mortality in the UK as compared to other countries in Western Europe, suggested by a study published in BMJ Open in 2017

Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology and the presence of huge patient pool is driving the growth of the market in this region.

The Middle East and Africa hold the least share of the ascites market owing to the presence of poor and slow developing countries, especially, in African region.


The global ascites market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is classified into transudative ascites, and exudate ascites.

On the basis of the diagnosis, the market is segmented into ultrasound, CT scan, laparoscopy, angiography, and others.

On the basis of the treatment, the market is segmented into surgeries and others. The surgeries segment is further segmented into peritoneovenous shunting, liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), and other surgeries.

On the basis of the end -users, the market is segmented into hospital, and clinics, ambulatory surgical centers, diagnostic centers, and others.

Access Sample Report @